Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Presently amened) A compound of formula (I):



(I)

wherein:
R^1 represents a group selected from:











each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;

R^2 represents hydrogen, -C_{1-6}alkyl, -C_{1-3}alkylCONR^{a}R^b, -C_{1-3}alkylCO_2C_{1-4}alkyl, -CO_2C_{1-4}alkyl or -C_{1-3}alkylCO_2H;

R^a and R^b independently represent hydrogen, -C_{1-6}alkyl, or together with the N atom to which they are bonded form a 5-, 6- or 7- membered non-aromatic heterocyclic ring optionally ~~containing~~ consisting of an additional heteroatom selected from O, N or S(O)$_n$, optionally substituted by -C_{1-4}alkyl~~, and optionally the S heteroatom is substituted by one or more O, i.e. and represents S(O)$_n$~~;

n represents 0-2;

X represents phenyl or a 5- or 6- membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C_{1-4}alkyl, -C_{2-4}alkenyl, -CN, -CF_3, -NR^{a}R^b, -C_{0-4}alkylOR^e, -C(O)R^f and -C(O)NR^{a}R^b;

R^e represents hydrogen or -C_{1-6}alkyl;
R^f represents -C_{1-6}alkyl;

Y represents phenyl or a 5- or 6- membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group –C_{1-2}alkylNR^{c}R^d.

R^c and R^d, together with the nitrogen atom to which they are bonded, form a 4-membered heterocyclic ring optionally substituted by halogen, OH or –OC_{1-6}alkyl, or a 5- or 6- membered non-aromatic heterocyclic ring substituted by OH, –OC_{1-6}alkyl or 1 to 2 halogens, with the proviso that the substituent is not attached to a ring carbon atom adjacent to a heteroatom;

~~and/~~or pharmaceutically acceptable derivative thereof.

2. (Original) A compound according to claim 1 wherein R^1 represents a group selected from:






each ring of which optionally ~~contains~~ includes a further heteroatom N,
Z represents an optional substituent halogen,
alk represents alkylene or alkenylene,
T represents S, O or NH;
~~and/~~or pharmaceutically acceptable derivative thereof.

3. (Currently amended) A compound according to claim 1 ~~or claim 2~~ wherein R^2 represents hydrogen ~~and/~~or pharmaceutically acceptable derivative thereof.

4. (Currently amended) A compound according to ~~any one of~~ claim~~s~~ 1-~~3~~ wherein X represents phenyl or a 5 or 6 membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is optionally substituted by 0-2 groups selected from: halogen, -C_{1-4}alkyl or -NR^aR^b ~~and/~~or pharmaceutically acceptable derivative thereof.

5. (Currently amended) A compound according to ~~any one of~~ claim~~s~~ 1-4 wherein Y represents a 5 or 6 membered aromatic heterocyclic group ~~containing~~ consisting of at least one heteroatom selected from O, N or S, each of which is substituted by a group -$CH_2NR^cR^d$ ~~and/~~or pharmaceutically acceptable derivative thereof.

6. (Currently Amended) A compound ~~according to claim 1~~ selected from:
(1*E*)-*N*-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide;
N-(1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-2-(5-chloro-2-thienyl)ethanesulfonamide;
N-((3*S*)-1-{4-[2-(1-Azetidinylmethyl)-1*H*-imidazol-1-yl]-2-fluorophenyl}-2-oxo-3-pyrrolidinyl)-6-chloro-1-benzothiophene-2-sulfonamide;
(*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]ethenesulfonamide;
(1*E*)-2-(5-Chloro-2-thienyl)-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide;

6-Chloro-*N*-[1-(2-fluoro-4-{2-[(3-fluoro-1-pyrrolidinyl)methyl]-1*H*-imidazol-1-yl}phenyl)-2-oxo-3-pyrrolidinyl]-1-benzothiophene-2-sulfonamide; and
6-Chloro-*N*-{1-[2-fluoro-4-(2-{[3-(methyloxy)-1-azetidinyl]methyl}-1*H*-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl}-1-benzothiophene-2-sulfonamide formate; ~~and/~~or a pharmaceutically acceptable derivative thereof.

7. Cancelled.

8. (Currently amended) A pharmaceutical composition comprising a compound according to ~~any of~~ claims 1-~~6 and/~~or a pharmaceutically acceptable derivative thereof together with at least one pharmaceutical carrier ~~and/~~or excipient.

9. Cancelled.

10. (Original) A method of treating a patient suffering from a condition susceptible to amelioration by a Factor Xa inhibitor comprising administering a therapeutically effective amount of a compound according to ~~any of~~ claims 1-~~6 and/~~or a pharmaceutically acceptable derivative thereof.

11. (Original) A process for preparing a compound of formula (I) which comprises:

(a) reacting a compound of formula (II) or an acid addition salt thereof with a compound of formula (III) where V is a suitable leaving group:



(II)



(III)

OR:
(b) by reacting compounds of formula (I) where R^2 is hydrogen with compounds of formula (XI):

R^2—T (XI)

wherein R^2 is -C_{1-6}alkyl, -C_{1-3}alkylCONR^{a}R^b, -C_{1-3}alkylCO_2C_{1-4}alkyl, or -CO_2C_{1-4}alkyl and T is a suitable leaving group, optionally followed by removal of the alkyl protecting group where appropriate.